Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer

NCT07667400 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

120

Enrollment

NIH

Sponsor class

Conditions

Head and Neck Cancer
Head and Neck Squamous Cell Carcinoma
Paranasal Sinus Neoplasms
Nasopharyngeal Carcinoma
Oropharyngeal Squamous Cell Carcinoma
Hypopharyngeal Cancer
Carcinoma of Larynx
Oral Squamous Cell Carcinoma
Salivary Gland Cancer
Adenoid Cystic Carcinoma
Prostate Cancer
Metastatic Castration Resistant Prostate Cancer

Interventions

DRUG: SX-682
DRUG: DTX

Sponsor

National Cancer Institute (NCI)